Continued Development + European Patent According to the CDC, each year around 1.7M adults develop sepsis of which nearly 270,000 die as a result in the US alone. But what is sepsis and why is it so deadly? Sepsis is when the body has an extreme response to an infection which damages the body’s own tissue and functionality. Due to its unique nature, sepsis is treatable if it is identified and treated quickly. But current methods often take 12+ hours to test and diagnose a patient for sepsis which then they have a 22% mortality rate due to the extended time waiting for diagnosis without treatment. That's where $ASEP.C comes in. Their novel diagnosis allows patients to be tested for sepsis within an hour to save the much-needed time for treatment. And they’ve already conducted a clinical study which has proven the effectiveness of their new method.
Furthermore, $ASEP.C isn't just focusing on the diagnosis side, they're also developing a pharmaceutical peptide to help combat antibiotic-resistant biofilms. Current study results show promise with the peptide, and they're pursuing clinical validation in treating organisms associated with Sinusitis pathogens in a planned study in Vancouver.
$ASEP.C’s approach to both the treatment and diagnosis of currently underserved health issues is what sets them apart. Their extensive net of patents, IP, and funding from top institutions shows that they're getting closer and closer to regulatory approval, development, and revenue generation. Plus, a recent patent was granted in Europe which continues to open the door for a more global audience/potential markets for the sepsis diagnosis technology).
Overall, considering the $17M valuation and the huge amount of lives their technology can save, there's significant upside here as they continue to test, research, and close in on approval.